ࡱ> "Root Entry=4%@,FileHeaderKDocInfo^1BodyText [44[44$&'(*0+,-./)123456789:;Root Entry=4@,FileHeaderKDocInfo^1BodyText [44[44  !#8] <\><CHO cell factory engineering for controlled and efficient production of therapeutic proteins> <\Դ><Therapeutic protein production has been the major part of revenues in biopharmaceutical industries. Annual global market of biopharmaceuticals is estimated at US$ 199.7 billion in 2013 and is predicted to reach US$ 497.9 billion in 2020 according to a constant increase in the demand for therapeutic proteins in treating various diseases and clinical application. Chinese hamster ovary (CHO) cells are the primary expression system for manufacturing biopharmaceuticals because of their suitability for large scale culture and ability for proper protein folding, assembly and post-translational modification. CHO cells account for 35.5% of the total cumulative (1982 2014) biopharmaceutical product approvals since the first market approval of tissue plasminogen activator produced from recombinant CHO (rCHO) cells in 1987. With the growing demand for biopharmaceuticals, there have been tremendous advance>YGIF89aɻxxxkkk]]]PPPCCC555((( d`LH00`Hذ̘`H0|pdXL@`0H `H0`dHL`H0xp`XH@0d LȰ``HH00dLؘȀ`H0xp`XH@d0L `H0d`LH`H0|pdXL@0`$H`dHL00`HذȘdL0xp`XH@0` HdH0ȳ``HHdL0xp`XH@`0H Ը̰ĠऀؘpȈXxHp@h@d8`8X0xT0pH dxddxd`d`p`|``x`p``x`!, H*\ȰÇ#JHŋ3jȱǏ CIɓ(S\ɲ˗0cʜI͛8sɳϟ@ JѣH*]ʴӧPJJիXjʵׯ`ÊKYv`ZgoU\mҤ__xK_+^xǐ#KLyaf~8/`o=U͠M{Μ7t냭Qaglޮg!̻㸉=\]НhUݽZS}:(c;`Ԣo{wo}7V"af&aMzeWۃwԡzr'pr#_ѹ6Ӈqug}Wmh]!~NWV܉)ueDZBF\7[o%sm& [m%D%Ny2b`ʹٝ#)јNAQ: fbx]颞#z )`KLߪ.7*i%{梢YgScJzbja [)&g|+g8'r)vT" >:Rf:ޢЦ*s9./J"ᡮ觛)Ykڍ3.Բ"4˖,B/.*$2ܪ\ǰ:×3=슧ڳ.?յ~}~մǰڼ2<~|k;5opFKUg⬎׬K`ΙsIjm>բ,@ٴqڳ9X'?><%?HOC] l03[ ƢVf>紐|5!'9XUD/e;4ʍx< ެ2ea("22tK%o)n=сD'ŀ]Zϫ"tixPR%쨝naM٪ǵ]2aBPucMX\EySS&Win/b Gea3NZN[I'L1lV@KE(yLߤYbyRi~3V$O ю_4%77TbxH^k JkGԤ8A*謧}NޤK1ApSK|J") (9Zd6SQy {If^l$x'Q1kRJ̀*YZRkZ]M,Rh}#'f93b$Mqc+lY֙~58X;5r #)[q&xO*kCOLjͭ"SX-PE]ZPuя gt-|%M06fdDgoQ]ԽmYPeȆ9Һ7\|Zse1|R8ػłIzFk W.7 ֒9؉s@[mtg|\;|xůqp:f,[殈mtmYZ kq?`MZ`YLO2{Yc2_! UU4k(4{S%&2\GssKJqr[{PiCĄrѮA ^ m}>c-A/%Kv}˴vHWP Document FileoĚ;jI\F\b]N4',[~Ӱ՘3Mj M(&Y'uUU0N%iJ{8dSY͆ׄtѰu ,J=VuqqcN6 nfG_ US>&u+z$F!țknkKy`WP{nSr{U,)-ͥ7h:o}"BD^evz_}Ծ,;~JY!=cz'}ʕS].;W=AQmOګXc,޵Uv@huB&4~+M^r=F;Ex[#4oaְ~.v 3}8lO[1Ͽ8Xx ؀8Xx(; of t`a``a`0x  X d p|ajou2010D 2 10| ”| $ 2:36:28ajou8, 5, 8, 1232 WIN32LEWindows_7@m @[44@Ij2N/X7W̚/I`VkAfIY Wk@embܛ-H(~R v+u=x[G)+ Z<=ы XЗ٤M6~D0ɛ˼KʊEh.(G Ywm?Ǹĭbq-dkUk xX"NY 3ة  M2 gpi&-.6ӾvSuvuaBKIt5଴[XZjBR5?>)* >THќ@Q,pAta=xCzGX3=vmv[cL>f} qoNÚjeޚ;ghtoۯZ<)  *R录K;ߴoG7f[qxR2:NcIŭ˘&FƌgzYz ZWhj3µv?ce```bi`gaHdHbaHeP`8L0d0!c2 @̊ca`d@r `ZCX,l&(VF1 304k%ؠ"iZ@P # 'CȮ7`P& `gp9D(,@]Lpfbwv00,)r'CZ {-!|w1ny+LN$28ehzF&%Q0x j/%u@DO 6C,H,#GB!k0~ 6*7=M*Z:ҙ#?*?ӿT@Y~X+mj3'm[v|:j)%C$Mϼ5#cd߈cumulative (1982 2014) biopharmaceutical product approvals since the first market approval of tissue plasminogen activator produced from recombinant CHO (rCHO) cells in 1987. With the growing demand for biopharmaceuticals, there have been tremendous advance>V;lU3^l(BRRL$NMEDb=;^ϚPm)(@H H JDA¢RAJ%{{3o5وܹsoVh# /h;uߧF&@>N/(ޗ~W[?8]:deٷ\OOzN(TSZ Z>P pա-k-=GXsŲ;빊ì&~mlwpeR(*It*4ѐU95ojrPEωboM:cߍDq=sϿTiKt}y9?3eTy$!UL%֪w|״Dяݞ.&@)\Iqٝ.~C>ލ0:9V=ճ():=ܣ0:ܴ֨ʰG1Ԣ6><'"cJ=h:nf64L냷A!_k)mJBH!keRN#Êحkե&|n!zgfgԠbNLD^ȔgN ?m:3A#!]nv2tP"3Q:oFMpx@vldO:Sc)_Aifz# `;*hY I7vۻrc*-uDvo$m$,r_TENJ-vў[r\12事Y;ír4TԺ1beVM[U>y 3q@ul*yy/HT]t`B"#dV J A]n~ɝ s{w})Eer±ؖ}ϡ<ؒ("j\J<3|3#IEϙመM *# }|8ʊMUNd;{r>ft8YŌl"uvZj,y)/q%wanD='a0-z2 !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJOLMNPQRSTUWXYZ[\]_`abcdefghijklmnpqtuvwxyz{}~HwpSummaryInformation.VPrvImage u PrvTextDocOptions =4=4Section0|' ‡uq\Y[fJk bJSDs9eM9_FbW::'B*|N]9/ΊŸ,".t5Q&13% J۪:%xX T\|c;ZvGgԓZU$&u߄w^^^-Z]3*-gu/_yt$ ݥ֩kMR]% Diͼ&z<*TU{`Z?-\־Q7Y 7#hY<*էϨ-z;>P+܎w|IrcU6W믓ѧ4 e;t8 D?1\~܌3f.3f Ϛ1W0ĸČy"nj9̭f5`1c~&0cF`;u܌)6zŒ N1D3f20f̿xfxŌ͘}fI`}l| +fjl":0ۯorvkɌf$o͘~+0fdŦX-JD2|xLi@,+j;s-*}?iD*ɵ:a=m=M':LGtAɞt&cwfh,4~jLZ㥕 ڞ3VwV.ict;4|q=L}mAc>BPJeD(2ّUx^>s &ci2N'A<2on,n̚-2c3f1ݷ5Gw;Hi?VMkQ=oѤTDKuBHAJ%Jc1FMb0w\(Ԃ8iĝl܅}oLL&1%}}3g}`%S JuQ,t6|ħ4^e-`wSHb9dԔ81~ls#f)ܥ 0a04 ԟ16pjU*tv-j4Z57I^zl;bJ/5CR ä0@|;Œ _D$MG=wW̧!tM6'!i/P o{Ñ s&↍LGNc82W5*uuʌư^mi$~tj c; 5<&ޫnEVVf#s'W)+i^ks~ϵGoQ𬙩O tݭ)HwpSummaryInformation.VPrvImage u PrvTextDocOptions =4=4Scripts =4=4JScriptVersion r DefaultJScripto_LinkDocs Section0|'  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJOLMNPQRSTUWXYZ[\]_`abcdefghijklmnpqtuvwxyz{}~